Sunshine Biopharma closes $6 million public offering

Sunshine Biopharma Inc. (NASDAQ: SBFM) completed a previously announced public offering, securing approximately $6.0 million in gross proceeds before deducting placement agent fees and other expenses. The transaction was executed on a reasonable best efforts basis and closed on October 9, 2026.

The offering comprised 10,909,082 Common Units sold at a public offering price of $0.55 per unit. Each unit consists of one share of Common Stock or one Pre-Funded Warrant, paired with two Series D Warrants. Holders may exercise the Series D Warrants immediately to purchase one share of Common Stock per warrant at an initial exercise price of $0.66. These warrants expire five years after their initial issuance date, though the exercise price and share count are subject to adjustment as detailed in the final prospectus.

Sunshine Biopharma stated that it expects to use the net proceeds for general corporate purposes and working capital. If the Series D Warrants are fully exercised on a cash basis, the company could receive an additional approximately $14.4 million in gross proceeds. The company noted that no assurance can be given that any warrants will be exercised.

Aegis Capital Corp. acted as the exclusive placement agent for the offering. Sichenzia Ross Ference Carmel LLP served as counsel to Sunshine Biopharma, while Kaufman & Canoles, P.C. represented Aegis Capital Corp. The U.S. Securities and Exchange Commission declared the registration statement on Form S-1 effective on October 7, 2026, after it was filed on October 2, 2026.

The company currently markets 61 generic prescription drugs in Canada. It intends to introduce roughly 11 new products later in 2026. Sunshine Biopharma is also developing two proprietary candidates: K1.1 mRNA, an mRNA-Lipid Nanoparticle therapeutic for liver cancer, and a PLpro protease inhibitor, a small-molecule antiviral for SARS-related coronavirus infections. Camille Sebaaly serves as the company's Chief Financial Officer.